FILE - The Biogen Inc., headquarters, March 11, 2020, in Cambridge, Mass. Several health plans will not cover the new Alzheimer's treatment Leqembi for part of their customer base, exposing those patients to thousands of dollars in potential costs. About 75% of the people taking Leqembi will be covered by Medicare, according to the Japanese drugmaker Eisai, which developed the drug and is co-marketing it with Cambridge, Massachusetts-based Biogen Inc. (AP Photo/Steven Senne, File) FILE PHOTO.

https://n.news.naver.com/mnews/article/077/0005998713?sid=104

#naver